Copyright
©The Author(s) 2015.
World J Hepatol. May 28, 2015; 7(9): 1184-1191
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1184
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1184
Liver failure |
Refractory ascites |
Encephalopathy |
Bilirubin level > 3 mg/dL |
Renal failure |
Creatinine > 2 mg/dL or creatinine clearance < 30 mL/min |
Coagulopathy |
Platelet count < 50 × 109/L |
Prothrombin time < 50% or prolonged > 4 s |
Portal hypertension |
Variceal bleeding within past 3 mo |
Varices at high risk of bleeding |
Circulatory impairment |
Main portal venous thrombosis |
Severely reduced portal flow or hepatofugal blood flow |
Untreatable arteriovenous fistula |
Hepatic artery thrombosis |
Severe atheromatosis |
- Citation: Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191
- URL: https://www.wjgnet.com/1948-5182/full/v7/i9/1184.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i9.1184